![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
Previous Article | Next Article 
Journal of Bacteriology, July 2004, p. 4808-4812, Vol. 186, No. 14
0021-9193/04/$08.00+0 DOI: 10.1128/JB.186.14.4808-4812.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
Laboratory of Bacterial Pathogenesis and Immunology, The Rockefeller University, New York, New York 10021
Received 6 February 2004/ Accepted 14 April 2004
 |
ABSTRACT |
|---|
 Top Abstract TextReferences |
|---|
|
TEXT |
|---|
|
TopAbstractTextReferences |
|---|
We are currently developing a novel approach to the control of pathogenic microorganisms through the action of purified bacteriophage lytic enzymes, termed lysins, produced during the natural life cycle of the bacteriophage. Lysins have evolved to rapidly break down the bacterial cell wall in order to release progeny phage (23). Structurally, lysins are commonly found as modular proteins with an amino-terminal domain that confers the enzymatic activity for a peptidoglycan bond and a carboxy-terminal domain that confers binding specificity to a carbohydrate epitope in the bacterial cell wall (13-15, 20). These highly evolved enzymes are normally very specific to the bacterial host of the phage from which they are derived (5, 6). When lysins are purified and applied extrinsically, their binding efficiency and catalytic activity can be harnessed to achieve targeted killing of select pathogenic bacteria with minimal effects on other commensal bacteria; this capacity is an advantage over conventional antibiotics. The efficacy of various lysins in killing Bacillus anthracis (19), Streptococcus pyogenes (a group A streptococcus) (17), and Streptococcus pneumoniae (10, 11) has been demonstrated both in vitro and in animal models of colonization and/or infection with these pathogens.
In this report, we describe a lysin, PlyV12, from the enterococcal bacteriophage 
1 which infects the host, E. faecalis strain V12. 1 (obtained from the d'Herelle collection, Laval University, Quebec, Canada) was originally isolated from sewage in 1975 and belongs to the Myoviridae family, whose members are characterized by contractile tails and icosahedral heads (2, 7). PlyV12 is a proposed amidase that exhibits a substantial lytic effect on multiple E. faecalis strains. Significantly, PlyV12 also lyses vancomycin-resistant strains of E. faecalis and strains of the closely related enterococcal pathogen E. faecium. Distinct from other reported lysins, PlyV12 was also found to be active against several disease-causing streptococcal and staphylococcal strains, making it one of the first lysins to demonstrate a spectrum of activity outside that of the host and closely related bacterial strains. This broad activity spectrum suggests the presence of a unique cell wall carbohydrate epitope common to these diverse human pathogens.
PlyV12 was identified based on a previously described genetic screening process (12) whereby a 1 genomic library was screened for lytic agents active against E. faecalis strain V12. A 945-bp open reading frame was identified after DNA sequencing of a lytic clone. The open reading frame translates into a protein of 314 amino acids with a molecular mass of approximately 34 kDa. The plyV12 gene was initially cloned into several Escherichia coli expression systems; however, the enzyme yields were very low in all cases. PlyV12 (as other lytic enzymes) is translated without a leader sequence; thus, it remains in the cytoplasm, where it cannot exert an effect on its peptidoglycan substrate, therefore making it possible to be expressed in a wide range of systems. Subsequently, the plyV12 gene and approximately 100 bp of the flanking sequence were amplified by PCR and cloned into the E. coli-Bacillus shuttle vector pDG148 (21), yielding pPY1. plyV12 was then expressed in Bacillus megaterium strain WH320 (MoBiTec, Marco Island, Fla.) by induction with isopropyl-ß-D-thiogalactopyranoside for 1 h, at which time the culture was centrifuged. The pelleted bacteria were suspended in 100 ml of a lysis reagent, BugBuster (diluted from a 10x concentration to a 1x concentration in phosphate-buffered saline [PBS] containing 100 µg of lysozyme/ml) (Novagen, San Diego, Calif.). This cell lysate was allowed to remain at 37°C for 1 h, followed by centrifugation at 4,000 rpm in an Eppendorf centrifuge to pellet the cell debris. The supernatant containing the crude lysin was diluted 1:3 in 50 mM morpholineethanesulfonic acid at pH 6.7 prior to being loaded on three 5-ml HiTrap SP HP columns (Amersham Biosciences, Piscataway, N.J.) connected in a series. The columns were washed with the 50 mM morpholineethanesulfonic acid buffer until the optical density at a wavelength of 280 nm (OD280) reached the baseline. PlyV12 was eluted with a 20-column-volume linear gradient to a concentration of 1 M sodium chloride (NaCl), and a peak at 
330 mM NaCl was found to contain the lytic activity. Furthermore, sodium dodecyl sulfate-polyacrylamide gel electrophoresis revealed a 34-kDa band corresponding to this peak, which matched the predicted size of PlyV12. Fractions constituting the peak were pooled and concentrated to 25 U/ml (see below) in an Amicon Ultra unit with a cutoff of 10 kDa (Millipore, Billerica, Mass.). The final PlyV12 sample was purified >85% based on spot densitometry (AlphaImager; Alpha Innotech, San Leandro, Calif.) of the gel images of crude and purified PlyV12 that were obtained by sodium dodecyl sulfate-polyacrylamide gel electrophoresis.
PlyV12 lytic activity was expressed in units per milliliter, in which units represent the reciprocal of the highest dilution of enzyme resulting in a 50% reduction in bacterial OD600 in 15 min. Subsequent bacterial killing experiments were carried out with a PlyV12 preparation of 25 U/ml.
For the lysin killing assays, the bacterial strains to be assayed were grown to mid-logarithmic phase in brain heart infusion broth, pelleted, and resuspended in PBS at pH 7.4 to an OD600 of 2.0. The pH profile experiments for PlyV12 activity were performed after the bacterial cells were resuspended in 100 mM acetate buffer at pH 5.2, 100 mM morpholinepropanesulfonic acid at pH 6.5, or 100 mM Tris at pH 7.5 or 8.5 instead. A 100-µl volume of bacterial suspension was mixed with 100 µl of PlyV12 at 25 U/ml. For the OD assays, the OD600 of the mixture was monitored every 15 s with shaking over a 15-min period on an automated 96-well plate reader (SpectraMax Plus384; Molecular Devices, Sunnyvale, Calif.). For viability assays, the mixture of a bacteria and PlyV12 was incubated at room temperature with gentle shaking for specified amounts of time, and at designated time points, aliquots were removed, serially diluted, and plated on agar plates for viability counts.
An alignment of the PlyV12 sequence from E. faecalis bacteriophage 1 with lysins from bacteriophages of Streptococcus agalactiae (a group B streptococcus), S. pyogenes, S. pneumoniae, Streptococcus mitis, and Streptococcus thermophilus revealed similarities primarily limited to the amino termini of these molecules, which correspond to the catalytic domains of most lysins (Fig. 1). Since several of these lysins are known to confer N-acetylmuramyl-L-alanine amidase activity, PlyV12 may also be an amidase. The diminished sequence similarity among the carboxy-terminal portions of all these lysins suggests that they have distinct cell wall binding epitopes and hence different bacterial specificities.
|
|
1 with lysins of group A and group B streptococcal bacteriophages (from S. pyogenes and S. agalactiae, respectively) (Fig. 1) suggests that these lysins target different cell wall epitopes, the ability of PlyV12 to lyse strains of E. faecalis, S. pyogenes, and group B streptococci shows that PlyV12 recognizes a receptor common among these different pathogens. Additionally, PlyV12 had some lytic effect against Staphylococcus aureus, another high-level, antibiotic-resistant nosocomial pathogen that is responsible for sepsis, necrotizing pneumonia, and toxic shock syndrome (22).
|
|
PlyV12 has bactericidal activity against all strains of E. faecalis and E. faecium tested, which is very significant for clinical strains and strains resistant to the antibiotic vancomycin. Vancomycin is considered the last line of defense against many bacterial pathogens that are already resistant to other available antibiotics (3). Enterococci are a leading cause of nosocomial infections, and treating these infections with conventional antibiotics has become increasingly difficult in light of the acquisition of antibiotic resistance genes by these organisms. It is anticipated that soon enterococci will be untreatable by current antibiotics, and alternative means of combating infections caused by these organisms will be urgently needed. We have shown that PlyV12 is a viable candidate for such an antienterococcal therapeutic agent.
PlyV12 exhibited significant lethal activity against other pathogens, such as S. pyogenes and group B, C, E, and G streptococci, with minimal effects against commensal bacteria (with the exception of Streptococcus gordonii). This finding suggests a broader application for this lysin whereby PlyV12 is used as a therapeutic agent specific for multiple pathogens that are responsible for serious infections. While the organization of its primary structure and the nature of its enzymatic activity make PlyV12 consistent with other bacteriophage lysins previously studied, PlyV12 is believed to be the first bacteriophage lysin described to have activity against Enterococcus species. In addition, previously studied bacteriophage lysins generally have a narrow spectrum of activity specific to the host bacterial species from which the phage was isolated. PlyV12's comparatively broad spectrum of activity against numerous bacterial strains indicates that this is a truly unique enzyme. Furthermore, the PlyV12 binding activity determined in this study suggests a previously undiscovered surface structure common to several different pathogens, which could serve as a target in the development of new antibiotics.
Nucleotide sequence accession number. The nucleotide sequence of PlyV12 has been deposited into GenBank under accession number AY581208.
|
ACKNOWLEDGMENTS |
|---|
We thank Alexander Tomasz for providing the bacterial strains and Vasant Kumar for plasmid pDG148.
|
FOOTNOTES |
|---|
|
REFERENCES |
|---|
|
TopAbstractTextReferences |
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Appl. Environ. Microbiol. | Infect. Immun. | Eukaryot. Cell |
|---|---|---|
| Mol. Cell. Biol. | J. Virol. | Microbiol. Mol. Biol. Rev. |
| ALL ASM JOURNALS |
Sa2 from S. agalactiae, a group B streptococcus, (Sa); 315.3 from S. pyogenes, a group A streptococcus (Spy); Dp-1 from S. pneumoniae (Spn); SM1 from S. mitis (Sm); and Sfi19 from S. thermophilus (St). Identical residues are highlighted by black boxes, while conserved residues are highlighted with gray boxes.
